Varda Rotter - Publications

Affiliations: 
MCB Molecular Cell Biology Weizmann Institute of Science, Rehovot, Israel 
Area:
Molecular Biology

267 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Retraction: Transactivation of the Gene Contributes to Mutant p53 Gain of Function. Cancer Research. 79: 2085. PMID 30987981 DOI: 10.1158/0008-5472.CAN-19-0560  0.68
2019 Koifman G, Aloni-Grinstein R, Rotter V. p53 balances between tissue hierarchy and anarchy. Journal of Molecular Cell Biology. PMID 30925590 DOI: 10.1093/jmcb/mjz022  0.72
2019 Klug YA, Schwarzer R, Rotem E, Charni M, Nudelman A, Gramatica A, Zarmi B, Rotter V, Shai Y. The HIV gp41 fusion protein inhibits T cell activation through the lentiviral lytic peptide 2 motif. Biochemistry. PMID 30602116 DOI: 10.1021/acs.biochem.8b01175  0.72
2018 Lonetto G, Koifman G, Silberman A, Attery A, Solomon H, Levin-Zaidman S, Goldfinger N, Porat Z, Erez A, Rotter V. Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy. Cell Death and Differentiation. PMID 30413783 DOI: 10.1038/s41418-018-0227-z  0.68
2018 Koifman G, Shetzer Y, Eizenberger S, Solomon H, Rotkopf R, Molchadsky A, Lonetto G, Goldfinger N, Rotter V. A mutant p53-dependent embryonic stem cell gene signature is associated with augmented tumorigenesis of stem cells. Cancer Research. PMID 30154152 DOI: 10.1158/0008-5472.CAN-18-0805  1
2018 Aloni-Grinstein R, Charni-Natan M, Solomon H, Rotter V. p53 and the Viral Connection: Back into the Future . Cancers. 10. PMID 29866997 DOI: 10.3390/cancers10060178  0.72
2018 Charni-Natan M, Solomon H, Molchadsky A, Jacob-Berger A, Goldfinger N, Rotter V. Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner. Cell Death & Disease. 9: 647. PMID 29844359 DOI: 10.1038/s41419-018-0697-4  1
2018 Rotem E, Faingold O, Charni M, Klug YA, Harari D, Shmuel-Galia L, Nudelman A, Rotter V, Shai Y. The HTLV-1 gp21 fusion peptide inhibits antigen specific T-cell activation in-vitro and in mice. Plos Pathogens. 14: e1007044. PMID 29727445 DOI: 10.1371/journal.ppat.1007044  0.72
2018 Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, Charni M, Rabani S, Koifman G, Tarcic O, Porat Z, Kogan-Sakin I, Goldfinger N, Oren M, Harris CC, ... ... Rotter V, et al. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene. PMID 29343849 DOI: 10.1038/s41388-017-0060-8  1
2017 Solomon H, Bräuning B, Fainer I, Ben-Nissan G, Rabani S, Goldfinger N, Moscovitz O, Shakked Z, Rotter V, Sharon M. Post-translational regulation of p53 function through 20S proteasome-mediated cleavage. Cell Death and Differentiation. PMID 28885617 DOI: 10.1038/cdd.2017.139  0.68
2017 Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic work-up and therapy. Blood. PMID 28607134 DOI: 10.1182/blood-2017-02-763086  1
2017 Wortzel I, Koifman G, Rotter V, Seger R, Porat Z. High Throughput Analysis of Golgi Structure by Imaging Flow Cytometry. Scientific Reports. 7: 788. PMID 28400563 DOI: 10.1038/s41598-017-00909-y  0.6
2017 Molchadsky A, Rotter V. p53 and its mutants on the slippery road from stemness to carcinogenesis. Carcinogenesis. PMID 28334334 DOI: 10.1093/carcin/bgw092  1
2016 Grespi F, Landré V, Molchadsky A, Di Daniele N, Marsella LT, Melino G, Rotter V. Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells. Cell Death & Disease. 7: e2567. PMID 28032868 DOI: 10.1038/cddis.2016.419  1
2016 Shetzer Y, Napchan Y, Kaufman T, Molchadsky A, Tal P, Goldfinger N, Rotter V. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors. International Journal of Cancer. PMID 28008605 DOI: 10.1002/ijc.30554  1
2016 Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V. p53 on the crossroad between regeneration and cancer. Cell Death and Differentiation. PMID 27768121 DOI: 10.1038/cdd.2016.117  1
2016 Isaac R, Goldstein I, Furth N, Zilber N, Streim S, Boura-Halfon S, Elhanany E, Rotter V, Oren M, Zick Y. TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response. Cell Death and Differentiation. PMID 27740623 DOI: 10.1038/cdd.2016.108  0.52
2016 Morel M, Shtrahman R, Rotter V, Nissim L, Bar-Ziv RH. Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits. Proceedings of the National Academy of Sciences of the United States of America. PMID 27385823 DOI: 10.1073/pnas.1604391113  0.4
2016 Stock K, Estrada MF, Vidic S, Gjerde K, Rudisch A, Santo VE, Barbier M, Blom S, Arundkar SC, Selvam I, Osswald A, Stein Y, Gruenewald S, Brito C, van Weerden W, ... Rotter V, et al. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. Scientific Reports. 6: 28951. PMID 27364600 DOI: 10.1038/srep28951  0.44
2016 Oren M, Tal P, Rotter V. Targeting mutant p53 for cancer therapy. Aging. PMID 27347904  0.56
2016 Shetzer Y, Molchadsky A, Rotter V. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. Cold Spring Harbor Perspectives in Medicine. PMID 27235476 DOI: 10.1101/cshperspect.a026203  1
2016 Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget. PMID 26943582 DOI: 10.18632/oncotarget.7857  0.76
2015 Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death and Differentiation. PMID 26358154 DOI: 10.1038/cdd.2015.119  0.76
2015 Rivlin N, Koifman G, Rotter V. p53 orchestrates between normal differentiation and cancer. Seminars in Cancer Biology. 32: 10-7. PMID 24406212 DOI: 10.1016/j.semcancer.2013.12.006  0.76
2015 Sommer P, Rotter VS, Ueberschaar M. Battery related cobalt and REE flows in WEEE treatment Waste Management. 45. DOI: 10.1016/j.wasman.2015.05.009  0.36
2015 Ueberschaar M, Rotter VS. Enabling the recycling of rare earth elements through product design and trend analyses of hard disk drives Journal of Material Cycles and Waste Management. 17: 266-281. DOI: 10.1007/s10163-014-0347-6  0.36
2014 Charni M, Rivlin N, Molchadsky A, Aloni-Grinstein R, Rotter V. p53 in liver pathologies-taking the good with the bad. Journal of Molecular Medicine (Berlin, Germany). 92: 1229-34. PMID 25404244 DOI: 10.1007/s00109-014-1223-5  0.76
2014 Solomon H, Sharon M, Rotter V. Modulation of alternative splicing contributes to cancer development: Focusing on p53 isoforms, p53β and p53γ Cell Death and Differentiation. 21: 1347-1349. PMID 25109594 DOI: 10.1038/cdd.2014.99  0.76
2014 Chang F, Lemmon CA, Nilaratanakul V, Rotter V, Romer L. Endothelial matrix assembly during capillary morphogenesis: insights from chimeric TagRFP-fibronectin matrix. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 62: 774-90. PMID 25063001 DOI: 10.1369/0022155414547419  0.76
2014 Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, ... Rotter V, et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proceedings of the National Academy of Sciences of the United States of America. 111: 11145-50. PMID 25024203 DOI: 10.1073/pnas.1404139111  0.76
2014 Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, ... ... Rotter V, et al. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death and Differentiation. 21: 1419-31. PMID 24832469 DOI: 10.1038/cdd.2014.57  0.76
2014 Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation. Proceedings of the National Academy of Sciences of the United States of America. 111: 7006-11. PMID 24778235 DOI: 10.1073/pnas.1320428111  0.76
2014 Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V. The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis. 35: 1196-208. PMID 24658181 DOI: 10.1093/carcin/bgu073  0.76
2014 Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A. The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells. Bmc Cancer. 14: 158. PMID 24598028 DOI: 10.1186/1471-2407-14-158  0.68
2014 Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V. p53: the barrier to cancer stem cell formation. Febs Letters. 588: 2580-9. PMID 24560790 DOI: 10.1016/j.febslet.2014.02.011  0.76
2013 Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V. p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer & Metabolism. 1: 9. PMID 24280180 DOI: 10.1186/2049-3002-1-9  0.68
2013 Madar S, Goldstein I, Rotter V. 'Cancer associated fibroblasts'--more than meets the eye. Trends in Molecular Medicine. 19: 447-53. PMID 23769623 DOI: 10.1016/j.molmed.2013.05.004  0.76
2013 Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 23: 634-46. PMID 23680148 DOI: 10.1016/j.ccr.2013.03.022  0.76
2013 Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta Plos One. 8. PMID 23630584 DOI: 10.1371/journal.pone.0061353  0.76
2013 Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death and Differentiation. 20: 774-83. PMID 23412343 DOI: 10.1038/cdd.2013.9  0.76
2013 Kaazke J, Meneses M, Wilke BM, Rotter VS. Environmental evaluation of waste treatment scenarios for the towns Khanty-Mansiysk and Surgut, Russia Waste Management and Research. 31: 315-326. PMID 23381971 DOI: 10.1177/0734242X12473792  0.36
2013 Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V. Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis. 34: 190-8. PMID 23054612 DOI: 10.1093/carcin/bgs318  0.76
2013 Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S, Shetzer Y, Rivlin N, Goldfinger N, Sarig R, Rotter V. p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death and Differentiation. 20: 312-20. PMID 22996684 DOI: 10.1038/cdd.2012.125  0.76
2013 Siebel MA, Rotter VS, Nabende A, Gupta J. Clean development mechanism: A way to sustainable waste management in developing countries? Osterreichische Wasser- Und Abfallwirtschaft. 65: 42-46. DOI: 10.1007/s00506-012-0052-4  0.36
2013 Rotter VS, Chancerel P, Ueberschaar M. Recycling-oriented product characterization for electric and electronic equipment as a tool to enable recycling of critical metals Tms Annual Meeting. 192-201.  0.36
2012 Leibovich-Rivkin T, Buganim Y, Solomon H, Meshel T, Rotter V, Ben-Baruch A. Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations. Cancers. 4: 55-76. PMID 24213226 DOI: 10.3390/cancers4010055  0.68
2012 Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, Horn-Saban S, Zalcenstein DA, Goldfinger N, Zundelevich A, Gal-Yam EN, Rotter V, Tanay A. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nature Genetics. 44: 1207-14. PMID 23064413 DOI: 10.1038/ng.2442  0.76
2012 Heidegger I, Ofer P, Doppler W, Rotter V, Klocker H, Massoner P. Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology. 153: 4633-43. PMID 22903612 DOI: 10.1210/en.2012-1348  0.76
2012 Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. Journal of Cell Science. 125: 5578-86. PMID 22899716 DOI: 10.1242/jcs.106815  0.76
2012 Goldstein I, Rotter V. Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends in Endocrinology and Metabolism: Tem. 23: 567-75. PMID 22819212 DOI: 10.1016/j.tem.2012.06.007  0.76
2012 Goldstein I, Madar S, Rotter V. Cancer research, a field on the verge of a paradigm shift? Trends in Molecular Medicine. 18: 299-303. PMID 22609171 DOI: 10.1016/j.molmed.2012.04.002  0.76
2012 Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, Goldstein I, Brosh R, Kalo E, Beatus T, Goldfinger N, Rotter V. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. Journal of Cell Science. 125: 3144-52. PMID 22427690 DOI: 10.1242/jcs.099663  0.76
2012 Kravchenko-Balasha N, Levitzki A, Goldstein A, Rotter V, Gross A, Remacle F, Levine RD. On a fundamental structure of gene networks in living cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 4702-7. PMID 22392990 DOI: 10.1073/pnas.1200790109  0.76
2012 Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V. p53, a novel regulator of lipid metabolism pathways. Journal of Hepatology. 56: 656-62. PMID 22037227 DOI: 10.1016/j.jhep.2011.08.022  0.76
2012 Reck BK, Rotter VS. Comparing growth rates of nickel and stainless steel use in the early 2000s Journal of Industrial Ecology. 16: 518-528. DOI: 10.1111/j.1530-9290.2012.00499.x  0.36
2012 Rotter VS, Chancerel P. Recycling of critical resources - Upgrade introduction Electronics Goes Green 2012+, Ecg 2012 - Joint International Conference and Exhibition, Proceedings 0.36
2012 Gotze R, Rotter VS. Challenges for the recovery of critical metals from waste electronic equipment - A case study of indium in LCD panels Electronics Goes Green 2012+, Ecg 2012 - Joint International Conference and Exhibition, Proceedings 0.36
2011 Madar S, Goldstein I, Neeman O, Rotter V. Beyond tumor suppression: p53 controls blastocyst implantation. Cell Cycle (Georgetown, Tex.). 10: 4203. PMID 22157227 DOI: 10.4161/cc.10.24.18412  0.76
2011 Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. The Journal of Pathology. 225: 475-8. PMID 22025211 DOI: 10.1002/path.2988  0.76
2011 Rotter VS. Waste management and producer responsibility: A score behind - A new ahead Waste Management and Research. 29: 889-890. PMID 21900358 DOI: 10.1177/0734242X11419553  0.36
2011 Buganimy Y, Madary S, Rais Y, Pomeraniec L, Harel E, Solomon H, Kalo E, Goldstein I, Brosh R, Haimov O, Avivi C, Polak-Charcon S, Goldfinger N, Barshack I, Rotter V. Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression Carcinogenesis. 32: 1749-1757. PMID 21900211 DOI: 10.1093/carcin/bgr203  0.76
2011 Rotter VS, Chancerel P, Schill WP. Practicalities of individual producer responsibility under the WEEE directive: Experiences in Germany Waste Management and Research. 29: 931-944. PMID 21824985 DOI: 10.1177/0734242X11415753  0.36
2011 Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes & Cancer. 2: 466-74. PMID 21779514 DOI: 10.1177/1947601911408889  0.76
2011 Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. Plos One. 6: e21650. PMID 21747944 DOI: 10.1371/journal.pone.0021650  0.76
2011 Madar S, Solomon H, Rotter V. Same stem cells but different: Isogenic embryonic stem cells harboring different p53 mutants. Cell Cycle (Georgetown, Tex.). 10: 2248-9. PMID 21670601 DOI: 10.4161/cc.10.14.15933  0.76
2011 Rinon A, Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R, Tzahor E. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development (Cambridge, England). 138: 1827-38. PMID 21447558 DOI: 10.1242/dev.053645  0.76
2011 Kravchenko-Balasha N, Remacle F, Gross A, Rotter V, Levitzki A, Levine RD. Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach. Bmc Systems Biology. 5: 42. PMID 21410932 DOI: 10.1186/1752-0509-5-42  0.76
2011 Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. Omics : a Journal of Integrative Biology. 15: 305-12. PMID 21332394 DOI: 10.1089/omi.2010.0084  0.76
2011 Madar S, Stambolsky P, Rotter V. Unleash the wild type: restoration of p53 suppressive activity in skin cancer. Cell Cycle (Georgetown, Tex.). 10: 736-7. PMID 21311232 DOI: 10.4161/cc.10.5.14928  0.76
2011 Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, Chakravarti D, Flores ER, Goldfinger N, Sarig R, Rotter V. SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Molecular and Cellular Biology. 31: 1679-89. PMID 21300779 DOI: 10.1128/MCB.01072-10  0.76
2011 Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. Plos One. 6: e14632. PMID 21297939 DOI: 10.1371/journal.pone.0014632  0.68
2011 Ke XS, Li WC, Hovland R, Qu Y, Liu RH, McCormack E, Thorsen F, Olsen JR, Molven A, Kogan-Sakin I, Rotter V, Akslen LA, Oyan AM, Kalland KH. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Experimental Cell Research. 317: 234-47. PMID 20969863 DOI: 10.1016/j.yexcr.2010.10.009  0.76
2011 Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies Cancer Gene Therapy. 18: 2-11. PMID 20966976 DOI: 10.1038/cgt.2010.63  0.76
2011 Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, ... ... Rotter V, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death and Differentiation. 18: 271-81. PMID 20689556 DOI: 10.1038/cdd.2010.94  0.76
2011 Chancerel P, Bolland T, Rotter VS. Status of pre-processing of waste electrical and electronic equipment in Germany and its influence on the recovery of gold Waste Management and Research. 29: 309-317. PMID 20406755 DOI: 10.1177/0734242X10368303  0.36
2011 Sarig R, Rotter V. Editorial: Can an iPS cell secure its genomic fidelity Cell Death and Differentiation. 18: 743-744. DOI: 10.1038/cdd.2011.14  0.76
2011 Zhao W, Ren H, Rotter VS. A system dynamics model for evaluating the alternative of type in construction and demolition waste recycling center - The case of Chongqing, China Resources, Conservation and Recycling. 55: 933-944. DOI: 10.1016/j.resconrec.2011.04.011  0.36
2010 Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. The Journal of Experimental Medicine. 207: 2127-40. PMID 20696700 DOI: 10.1084/jem.20100797  0.76
2010 Solomon H, Brosh R, Buganim Y, Rotter V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discovery Medicine. 9: 448-54. PMID 20515613  0.76
2010 Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis. 31: 1501-8. PMID 20504879 DOI: 10.1093/carcin/bgq101  0.76
2010 Brosh R, Sarig R, Natan EB, Molchadsky A, Madar S, Bornstein C, Buganim Y, Shapira T, Goldfinger N, Paus R, Rotter V. p53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss. Febs Letters. 584: 2473-7. PMID 20434500 DOI: 10.1016/j.febslet.2010.04.058  0.76
2010 Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, ... Rotter V, et al. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. Plos One. 5: e9657. PMID 20300178 DOI: 10.1371/journal.pone.0009657  0.76
2010 Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 17: 273-85. PMID 20227041 DOI: 10.1016/j.ccr.2009.11.025  0.76
2010 Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, ... ... Rotter V, et al. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Research. 70: 2274-84. PMID 20197462 DOI: 10.1158/0008-5472.CAN-09-2661  0.76
2010 Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspectives in Biology. 2: a001107. PMID 20182618 DOI: 10.1101/cshperspect.a001107  0.76
2010 Brosh R, Rotter V. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Molecular Biosystems. 6: 17-29. PMID 20024063 DOI: 10.1039/b911416e  0.76
2010 Zhao W, Leeftink RB, Rotter VS. Evaluation of the economic feasibility for the recycling of construction and demolition waste in China-The case of Chongqing Resources, Conservation and Recycling. 54: 377-389. DOI: 10.1016/j.resconrec.2009.09.003  0.36
2010 Ma W, Rotter VS, Shao D, Chen G. High temperature corrosion in a 24 MW waste-to-energy plant 18th Annual North American Waste-to-Energy Conference, Nawtec18. 301-306.  0.36
2009 Shalgi R, Brosh R, Oren M, Pilpel Y, Rotter V. Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate. Aging. 1: 762-70. PMID 20157565  0.76
2009 Lavelin I, Beer A, Kam Z, Rotter V, Oren M, Navon A, Geiger B. Discovery of novel proteasome inhibitors using a high-content cell-based screening system. Plos One. 4: e8503. PMID 20041034 DOI: 10.1371/journal.pone.0008503  0.76
2009 Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M. Silencing of the lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation Oncogene. 28: 4469-4479. PMID 19855428 DOI: 10.1038/onc.2009.270  0.76
2009 Goldstein I, Rotter V. Mutations in the tetramerization domain of p53: more than just keeping monomers apart. Cell Cycle (Georgetown, Tex.). 8: 3259-60. PMID 19823022  0.76
2009 Buganim Y, Rotter V. p53: balancing tumour suppression and implications for the clinic. European Journal of Cancer (Oxford, England : 1990). 45: 217-34. PMID 19775621 DOI: 10.1016/S0959-8049(09)70037-1  0.76
2009 Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Reviews. Cancer. 9: 701-13. PMID 19693097 DOI: 10.1038/nrc2693  0.76
2009 Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Molecular Cancer Research : McR. 7: 1212-23. PMID 19671672 DOI: 10.1158/1541-7786.MCR-09-0073  0.76
2009 Madar S, Goldstein I, Rotter V. Did experimental biology die? Lessons from 30 years of p53 research. Cancer Research. 69: 6378-80. PMID 19654301 DOI: 10.1158/0008-5472.CAN-09-0940  0.76
2009 Zemach A, Paul LK, Stambolsky P, Efroni I, Rotter V, Grafi G. The C-terminal domain of the Arabidopsis AtMBD7 protein confers strong chromatin binding activity. Experimental Cell Research. 315: 3554-62. PMID 19647732 DOI: 10.1016/j.yexcr.2009.07.022  0.76
2009 Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, Tzehoval E, Eisenbach L. The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. International Journal of Cancer. Journal International Du Cancer. 125: 2810-9. PMID 19544527 DOI: 10.1002/ijc.24669  0.76
2009 Peller S, Tabach Y, Rotschild M, Garach-Joshua O, Cohen Y, Goldfinger N, Rotter V. Identification of gene networks associated with erythroid differentiation. Blood Cells, Molecules & Diseases. 43: 74-80. PMID 19329339 DOI: 10.1016/j.bcmd.2009.01.020  0.68
2009 Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, Haukaas SA, Jonassen I, Petersen K, Goldfinger N, Rotter V, Akslen LA, Oyan AM, Kalland KH. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. Plos One. 4: e4687. PMID 19262738 DOI: 10.1371/journal.pone.0004687  0.68
2009 Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, Brosh R, Buganim Y, Goldfinger N, Klocker H, Schalken JA, Rotter V. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 30: 698-705. PMID 19233959 DOI: 10.1093/carcin/bgp043  0.76
2009 Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Journal of Molecular Biology. 385: 249-65. PMID 18996393 DOI: 10.1016/j.jmb.2008.10.063  0.56
2009 Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H, Rotter V. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis. 30: 20-7. PMID 18842679 DOI: 10.1093/carcin/bgn232  0.76
2009 Chancerel P, Meskers CEM, Hagelüken C, Rotter VS. Assessment of precious metal flows during preprocessing of waste electrical and electronic equipment Journal of Industrial Ecology. 13: 791-810. DOI: 10.1111/j.1530-9290.2009.00171.x  0.36
2009 Rotter VS, Chancerel P, Schill WP. Implementing Individual Producer Responsibility (IPR) under the European WEEE directive - Experiences in Germany 2009 Ieee International Symposium On Sustainable Systems and Technology, Issst '09 in Cooperation With 2009 Ieee International Symposium On Technology and Society, Istas. DOI: 10.1109/ISSST.2009.5156757  0.36
2009 Chancerel P, Rotter VS. Assessing the management of small Waste Electrical and Electronic Equipment through Substance Flow Analysis - The example of gold in Germany and the USA 2009 Ieee International Symposium On Sustainable Systems and Technology, Issst '09 in Cooperation With 2009 Ieee International Symposium On Technology and Society, Istas. DOI: 10.1109/ISSST.2009.5156718  0.36
2009 Chancerel P, Rotter VS. Assessing the management of small waste electrical an electronic equipment through substance flow analysis: The example of gold in Germany and the USA Revue De Metallurgie. Cahiers D'Informations Techniques. 106: 547-553.  0.36
2008 Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Børresen-Dale AL, Ginsberg D, ... ... Rotter V, et al. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Molecular Systems Biology. 4: 229. PMID 19034270 DOI: 10.1038/msb.2008.65  0.76
2008 Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R, Rotter V. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. Plos One. 3: e3707. PMID 19002260 DOI: 10.1371/journal.pone.0003707  0.76
2008 Ke XS, Qu Y, Goldfinger N, Rostad K, Hovland R, Akslen LA, Rotter V, Øyan AM, Kalland KH. Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. Plos One. 3: e3368. PMID 18852876 DOI: 10.1371/journal.pone.0003368  0.68
2008 Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G, Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (Georgetown, Tex.). 7: 1870-9. PMID 18594199  0.44
2008 Buganim Y, Rotter V. RHAMM in the complex p53 cell cycle network Cell Cycle. 7: 3291.  0.76
2007 Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Molecular and Cellular Biology. 27: 8228-42. PMID 17875924 DOI: 10.1128/MCB.00374-07  0.76
2007 Tabach Y, Brosh R, Buganim Y, Reiner A, Zuk O, Yitzhaky A, Koudritsky M, Rotter V, Domany E. Wide-scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site. Plos One. 2: e807. PMID 17726537 DOI: 10.1371/journal.pone.0000807  0.64
2007 Tang X, Milyavsky M, Goldfinger N, Rotter V. Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene. 26: 7302-12. PMID 17533371 DOI: 10.1038/sj.onc.1210542  0.76
2007 Shats I, Milyavsky M, Cholostoy A, Brosh R, Rotter V. Myocardin in tumor suppression and myofibroblast differentiation. Cell Cycle (Georgetown, Tex.). 6: 1141-6. PMID 17495540  0.76
2007 Efrati S, Berman S, Goldfinger N, Erez N, Averbukh Z, Golik A, Rotter V, Weissgarten J. Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension. Journal of Hypertension. 25: 1041-52. PMID 17414669 DOI: 10.1097/HJH.0b013e32807fb09c  0.76
2007 Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53 Oncogene. 26: 2202-2211. PMID 17401429 DOI: 10.1038/sj.onc.1210294  0.76
2007 Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, Oren M. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Research. 67: 2396-401. PMID 17363555 DOI: 10.1158/0008-5472.CAN-06-2425  0.64
2007 Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L, Kogan I, Cohen M, Shatz M, Madar S, Kalo E, Goldfinger N, Yuan J, Ron S, MacKenzie K, ... ... Rotter V, et al. Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell. 11: 133-46. PMID 17292825 DOI: 10.1016/j.ccr.2006.11.022  0.76
2006 Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, Kalis M, Goldfinger N, Rotter V. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Research. 66: 10750-9. PMID 17108111 DOI: 10.1158/0008-5472.CAN-06-0916  0.76
2006 Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V. Regulation of AIF expression by p53. Cell Death and Differentiation. 13: 2140-9. PMID 16729031 DOI: 10.1038/sj.cdd.4401965  0.76
2006 Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V. hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Research. 66: 3531-40. PMID 16585177 DOI: 10.1158/0008-5472.CAN-05-2183  0.76
2006 Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene. 25: 359-69. PMID 16170349 DOI: 10.1038/sj.onc.1209061  0.76
2005 Tabach Y, Milyavsky M, Shats I, Brosh R, Zuk O, Yitzhaky A, Mantovani R, Domany E, Rotter V, Pilpel Y. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Molecular Systems Biology. 1: 2005.0022. PMID 16729057 DOI: 10.1038/msb4100030  0.76
2005 Orgad S, Goldfinger N, Cohen G, Rotter V, Solomon B. Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein. Febs Letters. 579: 5609-15. PMID 16213502 DOI: 10.1016/j.febslet.2005.09.031  0.76
2005 Milyavsky M, Tabach Y, Shats I, Erez N, Cohen Y, Tang X, Kalis M, Kogan I, Buganim Y, Goldfinger N, Ginsberg D, Harris CC, Domany E, Rotter V. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Research. 65: 4530-43. PMID 15930270 DOI: 10.1158/0008-5472.CAN-04-3880  0.76
2005 Rotter VS, Schirmer M. Chlorine potential and chlorine species in waste fractions Chemie-Ingenieur-Technik. 77: 1158. DOI: 10.1002/cite.200590339  0.36
2004 Rotter VS, Kost T, Winkler J, Bilitewski B. Material flow analysis of RDF-production processes Waste Management. 24: 1005-1021. PMID 15567666 DOI: 10.1016/j.wasman.2004.07.015  0.36
2004 Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Research. 64: 8318-27. PMID 15548700 DOI: 10.1158/0008-5472.CAN-04-1145  0.76
2004 Herkel J, Kam N, Erez N, Mimran A, Heifetz A, Eisenstein M, Rotter V, Cohen IR. Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA. European Journal of Immunology. 34: 3623-32. PMID 15495163 DOI: 10.1002/eji.200425371  0.76
2004 Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. The Journal of Biological Chemistry. 279: 50976-85. PMID 15371422 DOI: 10.1074/jbc.M402502200  0.76
2004 Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 23: 5759-69. PMID 15208672 DOI: 10.1038/sj.onc.1207706  0.76
2004 Erez N, Stambolsky P, Shats I, Milyavsky M, Kachko T, Rotter V. Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter. Febs Letters. 567: 311-5. PMID 15178343 DOI: 10.1016/j.febslet.2004.05.003  0.76
2004 Mimran A, Mor F, Carmi P, Quintana FJ, Rotter V, Cohen IR. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. The Journal of Clinical Investigation. 113: 924-32. PMID 15067325 DOI: 10.1172/JCI17772  0.76
2004 Meerson A, Milyavsky M, Rotter V. p53 mediates density-dependent growth arrest Febs Letters. 559: 152-158. PMID 14960324 DOI: 10.1016/S0014-5793(04)00027-4  0.76
2004 Matas D, Milyavsky M, Shats I, Nissim L, Goldfinger N, Rotter V. p53 is a regulator of macrophage differentiation. Cell Death and Differentiation. 11: 458-67. PMID 14713961 DOI: 10.1038/sj.cdd.4401379  0.76
2004 Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis. 25: 11-9. PMID 14555612 DOI: 10.1093/carcin/bgg186  0.76
2003 Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Research. 63: 8777-83. PMID 14695194  0.76
2003 Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. The Journal of Clinical Investigation. 112: 1887-94. PMID 14679184 DOI: 10.1172/JCI19757  0.76
2003 Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A, Tabach Y, Goldfinger N, Ginsberg D, Harris CC, Rotter V. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Research. 63: 7147-57. PMID 14612508  0.76
2003 Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene. 22: 5667-76. PMID 12944915 DOI: 10.1038/sj.onc.1206724  0.76
2003 Peller S, Frenkel J, Lapidot T, Kahn J, Rahimi-Levene N, Yona R, Nissim L, Goldfinger N, Sherman DJ, Rotter V. The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts. Oncogene. 22: 4648-55. PMID 12879009 DOI: 10.1038/sj.onc.1206541  0.76
2003 Shats I, Milyavsky M, Erez N, Rotter V. The murine telomerase catalytic subunit shares the PAb-240 mutant specific epitope of the p53 protein. Febs Letters. 546: 321-4. PMID 12832061 DOI: 10.1016/S0014-5793(03)00607-0  0.76
2003 Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Human Mutation. 21: 277-84. PMID 12619113 DOI: 10.1002/humu.10190  0.76
2003 Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America. 100: 143-8. PMID 12518062 DOI: 10.1073/pnas.0237083100  0.76
2002 Herkel J, Modrow JP, Bamberger S, Kanzler S, Rotter V, Cohen IR, Lohse AW. Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis. Autoimmunity. 35: 493-6. PMID 12765474 DOI: 10.1080/0891693021000054075  0.76
2002 Haupt Y, Robles AI, Prives C, Rotter V. Deconstruction of p53 functions and regulation. Oncogene. 21: 8223-31. PMID 12447685 DOI: 10.1038/sj.onc.1206137  0.76
2002 Erez N, Milyavsky M, Goldfinger N, Peles E, Gudkov AV, Rotter V. Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene. 21: 6713-21. PMID 12360397 DOI: 10.1038/sj.onc.1205867  0.76
2002 Shakked Z, Yavnilovitch M, Kalb Gilboa AJ, Kessler N, Wolkowicz R, Rotter V, Haran TE. DNA binding and 3'-5' exonuclease activity in the murine alternatively-spliced p53 protein. Oncogene. 21: 5117-26. PMID 12140762 DOI: 10.1038/sj.onc.1205667  0.76
2002 Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S, Sidi Y. Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells Cancer Investigation. 20: 509-517. PMID 12094546 DOI: 10.1081/CNV-120002151  0.76
2002 Offer H, Erez N, Zurer I, Tang X, Milyavsky M, Goldfinger N, Rotter V. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis. 23: 1025-32. PMID 12082025  0.76
2001 Milyavsky M, Mimran A, Senderovich S, Zurer I, Erez N, Shats I, Goldfinger N, Cohen I, Rotter V. Activation of p53 protein by telomeric (TTAGGG)n repeats. Nucleic Acids Research. 29: 5207-15. PMID 11812854  0.76
2001 Uberti D, Piccioni L, Cadei M, Grigolato P, Rotter V, Memo M. p53 is dispensable for apoptosis but controls neurogenesis of mouse dentate gyrus cells following γ-irradiation Molecular Brain Research. 93: 81-89. PMID 11532341 DOI: 10.1016/S0169-328X(01)00180-2  0.76
2001 Sigal A, Matas D, Almog N, Goldfinger N, Rotter V. The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis. Oncogene. 20: 4891-8. PMID 11521201 DOI: 10.1038/sj.onc.1204724  0.76
2001 Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. The Embo Journal. 20: 4163-72. PMID 11483519 DOI: 10.1093/emboj/20.15.4163  0.76
2001 Almog N, Milyavsky M, Stambolsky P, Falcovitz A, Goldfinger N, Rotter V. The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop. Carcinogenesis. 22: 779-85. PMID 11323398  0.76
2001 Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, Rotter V. Structural and functional involvement of p53 in BER in vitro and in vivo. Oncogene. 20: 581-9. PMID 11313990 DOI: 10.1038/sj.onc.1204120  0.76
2001 Seluanov A, Gorbunova V, Falcovitz A, Sigal A, Milyavsky M, Zurer I, Shohat G, Goldfinger N, Rotter V. Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Molecular and Cellular Biology. 21: 1552-64. PMID 11238892 DOI: 10.1128/MCB.21.5.1552-1564.2001  0.76
2001 Offer H, Zurer I, Banfalvi G, Reha'k M, Falcovitz A, Milyavsky M, Goldfinger N, Rotter V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Research. 61: 88-96. PMID 11196204  0.76
2000 Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Research. 60: 6788-93. PMID 11156366  0.76
2000 Lilling G, Hacohen H, Nordenberg J, Livnat T, Rotter V, Sidi Y. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: Possible relation to high bcl-2/bax ratio? Cancer Letters. 161: 27-34. PMID 11078910 DOI: 10.1016/S0304-3835(00)00579-6  0.76
2000 Almog N, Goldfinger N, Rotter V. p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53 Oncogene. 19: 3395-3403. PMID 10918596  0.76
1999 Yaron Y, Schwartz D, Evans MI, Aloni R, Kapon A, Rotter V. p53 Tumor suppresser gene expression in the mouse ovary during an artificially induced ovulatory cycle Journal of Reproductive Medicine For the Obstetrician and Gynecologist. 44: 107-114. PMID 10853441  0.76
1999 Zhao W, He C, Rotter V, Merrick BA, Selkirk JK. An intragenic deletion of nuclear localization signal-1 of p53 tumor suppressor gene results in loss of apoptosis in murine fibroblasts. Cancer Letters. 147: 101-8. PMID 10660095 DOI: 10.1016/S0304-3835(99)00283-9  0.76
1999 Schwartz D, Goldfinger N, Kam Z, Rotter V. p53 Controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis Cell Growth and Differentiation. 10: 665-675. PMID 10547070  0.76
1999 Uberti D, Schwartz D, Almog N, Goldfinger N, Harmelin A, Memo M, Rotter V. Epithelial cells of different organs exhibit distinct patterns of p53- dependent and p53-independent apoptosis following DNA insult Experimental Cell Research. 252: 123-133. PMID 10502405 DOI: 10.1006/excr.1999.4606  0.76
1999 Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. Febs Letters. 450: 197-204. PMID 10359074 DOI: 10.1016/S0014-5793(99)00505-0  0.76
1999 Oren M, Rotter V. Introduction. p53: The first twenty years Cellular and Molecular Life Sciences. 55: 9-11. PMID 10065147 DOI: 10.1007/s000180050265  0.76
1999 Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V. Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin Molecular Brain Research. 65: 167-175. PMID 10064887 DOI: 10.1016/S0169-328X(98)00339-8  0.76
1999 Zhou X, Wang XW, Xu L, Hagiwara K, Nagashima M, Wolkowicz R, Zurer I, Rotter V, Harris CC. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Research. 59: 843-8. PMID 10029073  0.76
1999 Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma Oncology Reports. 6: 193-197. PMID 9864427  0.76
1998 Almog N, Rotter V. An insight into the life of p53: A protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998 Biochimica Et Biophysica Acta - Reviews On Cancer. 1378. PMID 9875245  0.76
1998 Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 16: 3269-77. PMID 9681825 DOI: 10.1038/sj.onc.1201867  0.76
1998 Prokocimer M, Peller S, Ben-Bassat H, Goldfinger N, Rotter V. P53 gene mutation in a T-acute lymphoblastic leukemia cell line (Loucy) with t(16:20) and 5q- chromosomal aberrations Leukemia and Lymphoma. 29: 607-611. PMID 9643574  0.76
1998 Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. Pooled analysis of p53 mutations in hematological malignancies Human Mutation. 12: 4-18. PMID 9633814 DOI: 10.1002/(SICI)1098-1004(1998)12:1<4::AID-HUMU2>3.0.CO;2-G  0.76
1998 Yaron Y, Schwartz D, Evans MI, Lessing JB, Rotter V. Alternatively spliced mRNA transcripts encoding the extracellular domain of the FSH receptor gene: Expression in the mouse ovary during the ovulatory cycle Journal of Reproductive Medicine For the Obstetrician and Gynecologist. 43: 435-438. PMID 9610467  0.76
1998 Wolkowicz R, Peled A, Elkind NB, Rotter V. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus Cancer Detection and Prevention. 22: 1-13. PMID 9466043  0.76
1998 Rotter V. Introduction Seminars in Cancer Biology. 8: 315-316. DOI: 10.1006/scbi.1998.0102  0.76
1997 Schwartz D, Rotter V. p53-dependent cell cycle control: Response to genotoxic stress Seminars in Cancer Biology. 8: 325-336. PMID 10101798 DOI: 10.1006/scbi.1998.0095  0.76
1997 Wolkowicz R, Rotter V. The DNA binding regulatory domain of p53: See the C Pathologie Biologie. 45: 785-796. PMID 9769942  0.76
1997 Schwartz D, Almog N, Peled A, Goldfinger N, Rotter V. Role of wild type p53 in the G2 phase: Regulation of the γ-irradiation-induced delay and DNA repair Oncogene. 15: 2597-2607. PMID 9399647  0.76
1997 Almog N, Rotter V. Involvement of p53 in cell differentiation and development Biochimica Et Biophysica Acta - Reviews On Cancer. 1333. PMID 9294016 DOI: 10.1016/S0304-419X(97)00012-7  0.76
1997 Rotter V, Ronen D. Expression of p53 in differentiation and apoptosis and its deregulation in tumor cell Leukemia. 11: 327-330. PMID 9209380  0.76
1996 Reisman D, Bálint E, Loging WT, Rotter V, Almon E. A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells Genomics. 38: 364-370. PMID 8975713 DOI: 10.1006/geno.1996.0639  0.76
1996 Peled A, Schwartz D, Elkind NB, Wolkowicz R, Li R, Rotter V. The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells Oncogene. 13: 1677-1685. PMID 8895513  0.76
1996 Schreiber L, Sharabi Y, Schwartz D, Goldfinger N, Brodie C, Rotter V, Shoham J. Induction of apoptosis and p53 expression in immature thymocytes by direct interaction with thymic epithelial cells Scandinavian Journal of Immunology. 44: 314-322. PMID 8845023  0.76
1996 Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels Cell Growth and Differentiation. 7: 21-30. PMID 8788030  0.76
1996 Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells Molecular and Cellular Biology. 16: 5178-5185. PMID 8756675  0.76
1996 Peled A, Zipori D, Rotter V. Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells Cancer Research. 56: 2148-2156. PMID 8616864  0.76
1995 Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V. A novel polymorphism in intron 6 of the human p53 gene: A possible association with cancer predisposition and susceptibility Dna and Cell Biology. 14: 983-990. PMID 8534372  0.76
1995 Aloni-Grinstein R, Schwartz D, Rotter V. Accumulation of wild-type p53 protein upon γ-irradiation induces a G2 arrest-dependent immunoglobulin κ light chain gene expression Embo Journal. 14: 1392-1401. PMID 7729417  0.76
1995 Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. Direct involvement of p53 in programmed cell death of oligodendrocytes Embo Journal. 14: 1136-1144. PMID 7720704  0.76
1995 Elkind NB, Goldfinger N, Rotter V. Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)n repeats Oncogene. 11: 841-851. PMID 7675445  0.76
1995 Wolkowicz R, Peled A, Elkind NB, Rotter V. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form Proceedings of the National Academy of Sciences of the United States of America. 92: 6842-6846. PMID 7624329  0.76
1995 Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V. p53 mutations in matched primary and metastatic human tumors Molecular Carcinogenesis. 13: 166-172. PMID 7619219 DOI: 10.1002/mc.2940130306  0.76
1995 Tendler Y, Schwartz Y, Reshef R, Shasha SM, Rotter V, Shkolnik T. Immunohistochemical detection of p53 protein expression in HPV-induced condyloma acuminatum Acta Dermato-Venereologica. 75: 177-179. PMID 7544519  0.76
1995 Wolkowicz R, Elkind NB, Ronen D, Rotter V. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes Oncogene. 10: 1167-1174. PMID 7535417  0.76
1994 Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages Blood. 84: 2391-2411. PMID 7919359  0.76
1993 Schwartz D, Goldfinger N, Rotter V. Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes Oncogene. 8: 1487-1494. PMID 8502474  0.76
1993 Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif Cell Growth &Amp; Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 4: 57-65. PMID 8494784  0.76
1993 Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif Oncogene. 8: 1183-1193. PMID 8479742  0.76
1993 Reisman D, Rotter V. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene Nucleic Acids Research. 21: 345-350. PMID 8441640 DOI: 10.1093/nar/21.2.345  0.76
1993 Foord O, Navot N, Rotter V. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein Molecular and Cellular Biology. 13: 1378-1384. PMID 8441383  0.76
1993 Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N, Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage Oncogene. 8: 3297-3305. PMID 8247532  0.76
1993 Almon E, Goldfinger N, Kapon A, Schwartz D, Levine AJ, Rotter V. Testicular tissue-specific expression of the p53 suppressor gene Developmental Biology. 156: 107-116. PMID 7680625 DOI: 10.1006/dbio.1993.1062  0.76
1993 Rotter V, Foord O, Navot N. In search of the functions of normal p53 protein Trends in Cell Biology. 3: 46-49. DOI: 10.1016/0962-8924(93)90151-P  0.76
1992 Ronen D, Teitz Y, Goldfinger N, Rotter V. Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses Nucleic Acids Research. 20: 3435-3441. PMID 1630914 DOI: 10.1093/nar/20.13.3435  0.76
1992 Landesman Y, Pagano M, Draetta G, Rotter V, Fusenig NE, Kimchi A. Modifications of cell cycle controlling nuclear proteins by transforming growth factor β in the HaCaT keratinocyte cell line Oncogene. 7: 1661-1665. PMID 1385861  0.76
1991 Rotter V, Prokocimer M. p53 And human malignancies Advances in Cancer Research. 57: 257-272. PMID 1950705  0.76
1991 Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro Proceedings of the National Academy of Sciences of the United States of America. 88: 8982-8986. PMID 1924360  0.76
1991 Foord OS, Bhattacharya P, Reich Z, Rotter V. A DNA binding domain is contained in the C-terminus of wild type p53 protein Nucleic Acids Research. 19: 5191-5198. PMID 1923804 DOI: 10.1093/nar/19.19.5191  0.76
1991 Ronen D, Rotter V, Reisman D. Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif Proceedings of the National Academy of Sciences of the United States of America. 88: 4128-4132. PMID 1851994  0.76
1991 Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization Cell Growth &Amp; Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 2: 661-667. PMID 1809377  0.76
1991 Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein Oncogene. 6: 2055-2065. PMID 1719467  0.76
1991 Shaulsky G, Rotter V, Goldfinger N. Alterations in Tumor Development in Vivo Mediated by Expression of Wild Type or Mutant p53 Proteins Cancer Research. 51: 5232-5237. PMID 1717142  0.68
1991 Peller S, Kaufman S, Rotter V. Immunophenotypes and gene rearrangements of the t-cell receptor in two patients with a large granular lymphocyte disorder Leukemia and Lymphoma. 6: 83-87. DOI: 10.3109/10428199109064883  0.76
1990 Trakhtenbrot L, Kelman Z, Rotter V, Haran-Ghera N. Chromosomal mapping of the murine c-abl proto-oncogene by in situ hybridization Leukemia. 4: 136-137. PMID 2406516  0.76
1990 Shaulsky G, Ben-Ze'ev A, Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells Oncogene. 5: 1707-1711. PMID 2267137  0.76
1990 Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis Molecular and Cellular Biology. 10: 6565-6577. PMID 2247074  0.76
1989 Reisman D, Rotter V. Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells Oncogene. 4: 945-953. PMID 2668845  0.76
1989 Reisman D, Rotter V. Induced expression from the Moloney murine leukemia virus long terminal repeat during differentiation of human myeloid cells is mediated through its transcriptional enhancer Molecular and Cellular Biology. 9: 3571-3575. PMID 2477690  0.76
1988 Pohl J, Goldfinger N, Radler-Pohl A, Rotter V, Schirrmacher V. p53 increases experimental metastatic capacity of murine carcinoma cells Molecular and Cellular Biology. 8: 2078-2081. PMID 3290647  0.76
1988 Reisman D, Greenberg M, Rotter V. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1 Proceedings of the National Academy of Sciences of the United States of America. 85: 5146-5150. PMID 2839831  0.76
1987 Shohat O, Greenberg M, Reisman D, Oren M, Rotter V. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense Oncogene. 1: 277-283. PMID 2455263  0.76
1986 Prokocimer M, Shaklai M, Ben Bassat H, Wolf D, Goldfinger N, Rotter V. Expression of p53 in human leukemia and lymphoma Blood. 68: 113-118. PMID 3521760  0.76
1986 Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V. Molecular basis for heterogeneity of the human p53 protein Molecular and Cellular Biology. 6: 4650-4656. PMID 3025664  0.76
1986 Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O, Rotter V. Immunologically distinct p53 molecules generated by alternative splicing Molecular and Cellular Biology. 6: 3232-3239. PMID 3023970  0.76
1986 Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Phillip Koeffler H. Human p53 gene localized to short arm of chromosome 17 Nature. 319: 783-784. PMID 3005871 DOI: 10.1038/319783a0  0.76
1985 Rotter V, Wolf D, Blick M, Nicolson GL. Expression of abl and other oncogenes is independent of metastatic potential in Abelson virus-transformed malignant murine large cell lymphoma Clinical &Amp; Experimental Metastasis. 3: 77-86. PMID 4042463 DOI: 10.1007/BF01758957  0.76
1985 Rotter V, Wolf D. Biological and molecular analysis of p53 cellular-encoded tumor antigen Advances in Cancer Research. 43: 113-141. PMID 3887856  0.76
1985 Wolf D, Laver-Rudich Z, Rotter V. In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene Molecular and Cellular Biology. 5: 1887-1893. PMID 3018534  0.76
1985 Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells Proceedings of the National Academy of Sciences of the United States of America. 82: 790-794. PMID 2858093  0.76
1985 Wolf D, Harris N, Goldfinger N, Rotter V. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule Molecular and Cellular Biology. 5: 127-132. PMID 2580227  0.76
1984 Rotter V, Wolft D, Nicolson GL. The expression of transformation-related protein p53 and p53-containing mRNA in murine RAW117 large cell lymphoma cells of differing metastatic potential Clinical &Amp; Experimental Metastasis. 2: 199-204. PMID 6399697 DOI: 10.1007/BF00132926  0.76
1984 Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 312: 649-51. PMID 6390217 DOI: 10.1038/312649a0  0.76
1984 Rotter V, Wolf D, Pravtcheva D, Ruddle FH. Chromosomal assignment of the murine gene encoding the transformation-related protein p53 Molecular and Cellular Biology. 4: 383-385. PMID 6366521  0.76
1984 Wolf D, Admon S, Oren M, Rotter V. Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species Molecular and Cellular Biology. 4: 552-558. PMID 6144042  0.76
1984 Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences Molecular and Cellular Biology. 4: 1402-1410. PMID 6095069  0.76
1984 Wolf D, Harris N, Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene Cell. 38: 119-126. PMID 6088057 DOI: 10.1016/0092-8674(84)90532-4  0.76
1983 Rotter V, Abutbul H, Ben-Ze'ev A. P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts Embo Journal. 2: 1041-1047. PMID 6354706  0.76
1983 Rotter V, Abutbul H, Wolf D. The presence of p53 transformation-related protein in Ab-MuLV transformed cells is required for their development into lethal tumors in mice International Journal of Cancer. 31: 315-320. PMID 6298128  0.76
1983 Rotter V, Friedman H, Katz A, Zerivitz K, Wolf D. Variation in antigenic determinants of p53 transformation-related protein obtained from various species Journal of Immunology. 131: 329-333. PMID 6190914  0.76
1983 Rotter V. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells Proceedings of the National Academy of Sciences of the United States of America. 80: 2613-2617. PMID 6189126  0.76
1981 Rotter V, Boss MA, Baltimore D. Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents Journal of Virology. 38: 336-346. PMID 6264107  0.76
1980 Rotter V, Witte ON, Coffman R, Baltimore D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50 Journal of Virology. 36: 547-555. PMID 6159484  0.76
1979 Rotter V, Yakir Y, Trainin N. Role of L-alanine in the response of human lymphocytes to PHA and Con A Journal of Immunology. 123: 1726-1731. PMID 573302  0.76
1979 Rotter V, Trainin N. Role of thymic hormone (THF) and of a thymic plasma recirculating factor (TPRF) in the modulation of human lymphocyte response to PHA and Con A Journal of Immunology. 122: 414-420. PMID 216747  0.76
1979 Trainin N, Rotter V, Yakir Y, Leve R, Handzel Z, Shohat B, Zaizov R. Biochemical and biological properties of THF in animal and human models Annals of the New York Academy of Sciences. 332: 9-22. PMID 43694  0.76
1978 Rotter V, Fink A, Trainin N. In vitro allogeneic response of human lymphocytes dependent upon dialyzable plasma components and a thymic hormone, THF Cellular Immunology. 36: 242-250. PMID 147137 DOI: 10.1016/0008-8749(78)90268-X  0.76
1977 Rotter V, Trainin N. Effect of thymic hormone on the response of different lymphoid cell populations to T mitogens Israel Journal of Medical Sciences. 13: 363-370. PMID 301520  0.76
1977 Zaizov R, Vogel R, Cohen I, Varsano I, Shohat B, Rotter V, Trainin N. Thymic hormone (THF) therapy in immunosuppressed children with lymphoproliferative neoplasia and generalized varicella Biomedicine Express. 27: 105-108. PMID 268220  0.76
1977 Varsano I, Schonfeld TM, Matoth Y, Shohat B, Englander T, Rotter V, Trainin N. Severe disseminated adenovirus infection successfully treated with a thymic humoral factor, THF. Acta Paediatrica Scandinavica. 66: 329-31. PMID 194457  0.76
1976 Rotter V, Trainin N. Depletion of suppressor T cells in syngeneic chimeric mice Advances in Experimental Medicine and Biology. 66: 593-598. PMID 1083656  0.76
1976 Rotter V, Schlesinger M, Kalderon R, Trainin N. Response of human lymphocytes to PHA and Con A, dependent on and regulated by THF, a thymic hormone Journal of Immunology. 117: 1927-1932. PMID 993589  0.76
1976 Rotter V, Schlesinger M, Kalderon R, Trainin N. Response of human lymphocytes to PHA and con A, dependent on and regulated by THF, and thymic hormone Journal of Immunology. 17.  0.76
1975 Rotter V, Trainin N. Inhibition of tumor growth in syngeneic chimeric mice mediated by a depletion of suppressor T cells Transplantation. 20: 68-74. PMID 1101476  0.76
1975 Rotter V, Trainin N. Increased mitogenic reactivity of normal spleen cells to T lectins induced by thymus humoral factor (THF) Cellular Immunology. 16: 413-421. PMID 1090382 DOI: 10.1016/0008-8749(75)90130-6  0.76
1975 Rotter V, Trainin N. Proceedings: Increased mitogenic reactivity of lymphoid cells to T lectins induced by thymus humoral factor Israel Journal of Medical Sciences. 11: 1381-1382. PMID 1082875  0.76
1975 Levo Y, Rotter V, Ramot B. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease Biomedicine Express. 23: 198-200. PMID 1082352  0.76
1975 Rotter V, Trainin N. Elimination of suppressor T-cells in mice undergoing a graft-versus-host reaction expressed by increased response to polyvinylpyrrolidone (PVP) Cellular Immunology. 18: 199-209. PMID 237632 DOI: 10.1016/0008-8749(75)90048-9  0.76
1974 Rotter V, Trainin N. Thymus cell population exerting a regulatory function in the immune response of mice to polyvinyl pyrrolidone Cellular Immunology. 13: 76-86. PMID 4615810 DOI: 10.1016/0008-8749(74)90228-7  0.76
1974 Trainin N, Levo Y, Rotter V. Resistance to hydrocortisone conferred upon thymocytes by a thymic humoral factor European Journal of Immunology. 4: 634-637. PMID 4154201  0.76
1973 Globerson A, Rotter V, Nakamura I, Trainin N. Thymus extracts induce differentiation of thymus derived cells. Advances in Experimental Medicine and Biology. 29: 183-9. PMID 4605385  0.76
1973 Rotter V, Globerson A, Nakamura I, Trainin N. Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor. The Journal of Experimental Medicine. 138: 130-42. PMID 4577615  0.76
1973 Lonai P, Mogilner B, Rotter V, Trainin N. Studies on the effect of a thymic humoral factor on differentiation of thymus derived lymphocytes European Journal of Immunology. 3: 21-26. PMID 4146225  0.76
1972 Pluznik DH, Rotter V, Scheinman R. Kinetics of proliferation of splenic macrophage precursor cells during the early primary immune response Res Journal of the Reticuloendothelial Society. 11: 154-166. PMID 4555127  0.76
Show low-probability matches.